Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for Daiichi Sankyo

    Client Virtual Booth

    DAIICHI SANKYO

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Daiichi Sankyo
    japan Flag
    Country
    Country
    Japan
    Address
    Address
    3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo 103-8426
    Telephone
    Telephone
    +81-3-6225-1111
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.daiichisankyo.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/daiichi-sankyo
    Twitter
    Twitter
    https://twitter.com/daiichisankyo?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    left grey arrow
    right gray arrow
    Full View ScreenFull Screen View
    US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors
    US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-daiichi-astrazeneca-drug-treatment-solid-tumors-2024-04-05/

    REUTERS
    06 Apr 2024
    Share Share
    ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy
    ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy

    https://www.businesswire.com/news/home/20240405182615/en

    BUSINESSWIRE
    05 Apr 2024
    Share Share
    Daiichi Sankyo's Enhertu (fam-trastuzumab deruxtecan-nxki) Receives Suppl Approval in the U.S.
    Daiichi Sankyo's Enhertu (fam-trastuzumab deruxtecan-nxki) Receives Suppl Approval in the U.S.

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761139

    FDA
    05 Apr 2024
    Share Share
    Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients
    Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients

    https://www.businesswire.com/news/home/20240402075330/en

    BUSINESSWIRE
    03 Apr 2024
    Share Share
    AZ & Daiichi Sankyo’s BLA for Dato-DXd accepted in the US for breast cancer
    AZ & Daiichi Sankyo’s BLA for Dato-DXd accepted in the US for breast cancer

    https://www.indianpharmapost.com/drug-approval/astrazeneca-and-daiichi-sankyos-bla-for-dato-dxd-accepted-in-the-us-for-treatment-of-breast-cancer-15473

    INDIANPHARMAPOST
    02 Apr 2024
    Share Share
    CHMP positive opinions for bempedoic acid and the bempedoic acid / ezetimibe
    CHMP positive opinions for bempedoic acid and the bempedoic acid / ezetimibe

    https://www.businesswire.com/news/home/20240322719062/en

    BUSINESSWIRE
    22 Mar 2024
    Share Share
    Two Datopotamab Deruxtecan Applications Validated in EU for Patients with NSCLC
    Two Datopotamab Deruxtecan Applications Validated in EU for Patients with NSCLC

    https://www.businesswire.com/news/home/20240301286060/en

    BUSINESSWIRE
    04 Mar 2024
    Share Share
    Daiichi Sankyo spends €1B to bulk up in ADCs
    Daiichi Sankyo spends €1B to bulk up in ADCs

    https://www.fiercepharma.com/pharma/daiichi-sankyo-plots-eu1b-expansion-beef-antibody-drug-conjugate-production-germany

    FIERCE PHARMA
    20 Feb 2024
    Share Share
    Dato-DXd BLA accepted in the US for patients with advanced nonsquamous NSCLC
    Dato-DXd BLA accepted in the US for patients with advanced nonsquamous NSCLC

    https://www.businesswire.com/news/home/20240219154771/en

    BUSINESSWIRE
    19 Feb 2024
    Share Share
    Daiichi invests 1 bln eur near Munich to make precision cancer drugs
    Daiichi invests 1 bln eur near Munich to make precision cancer drugs

    https://www.daiichi-sankyo.eu/media/european-news/news-detail/daiichi-sankyo-investiert-ca-eine-milliarde-euro-in-deutschland-standort-pfaffenhofen-bayern-wird-zu-internationalem-innovationszentrum-ausgebaut/

    PRESS RELEASE
    17 Feb 2024
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    polpharma-m-2024-04-15

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search